AU StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

TELIX PHARMACEUTICALS LTD

15.580

+0.0900.58%

Volume:1.27M

Turnover:19.89M

Market Cap:5.28B

PE:117.45

High:15.835

Open:15.400

Low:15.170

Close:15.490

52wk High:18.320

52wk Low:8.260

Shares:338.72M

Float Shares:275.41M

Volume Ratio:0.46

T/O Rate:0.46%

Dividend:- -

Dividend Rate:- -

EPS(TTM):0.133

EPS(LYR):-0.029

ROE:7.36%

ROA:2.71%

PB:7.78

PE(LYR):-530.96

Loading ...

Overview Company News Filings

NuWays reiterates Eckert & Ziegler buy rating, sets EUR 23 target price

Telix Pharmaceuticals Says JPMorgan Increases Stake

MT Newswires Live

Telix Pharmaceuticals Doses First Patient in Phase 3 Brain Cancer Trial

MT Newswires Live

Stock Track | Telix Pharmaceuticals Plummets 5.11% Intraday Following $600 Million Convertible Bond Offering

Telix Doses First Patient in Phase 3 Ipax-Bright Trial of Tlx101-Tx for Recurrent Glioblastoma

THOMSON REUTERS

Telix Doses First Patient in Phase 3 IPAX-BrIGHT Trial of TLX101-Tx for Recurrent Glioblastoma

Telix Successfully Prices and Upsizes US$600 Million Convertible Bonds

THOMSON REUTERS

Telix Pharmaceuticals Ltd - Initial Conversion Price of Convertible Bonds Is US$13.85 per Ordinary Share

THOMSON REUTERS

Telix Pharmaceuticals Ltd - Telix Successfully Prices Upsized US$600M Convertible Bonds

THOMSON REUTERS

Telix Pharmaceuticals Ltd - Upsizes Convertible Notes Due 2031 to US$600 Milion - SEC Filing

THOMSON REUTERS

Top Premarket Decliners

MT Newswires Live

BRIEF-Telix Pharmaceuticals Launches Offering Of $550 MLN Convertible Notes Due 2031 To Be Issued By Its Unit

Telix launches US$550 million convertible notes offering due 2031

Telix Refinances Convertible Bonds

Telix Pharmaceuticals Ltd - Launches an Offering of US$550 Mln Convertible Notes Due 2031 to Be Issued by Its Wholly-Owned Subsidiary

THOMSON REUTERS

Telix Pharmaceuticals Ltd - Initial Conversion Price Will Be at a Premium to Telix's Current Share Price.

THOMSON REUTERS

Regeneron Pharmaceuticals Inc - Telix Will Receive an Upfront Cash Payment of US$40 Mln From Regeneron

THOMSON REUTERS

BUZZ-Australia's Telix Pharmaceuticals rises on $40 mln Regeneron deal; Citi sees 'broader' scope

Stock Track | Telix Pharmaceuticals Soars 7.58% Intraday on Major Regeneron Collaboration Deal

Telix and Regeneron Announce Strategic Radiopharma Collaboration

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/stock/TLX.AU/news?page=8"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"TLX.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"TLX.AU\",,,,,undefined,":{"symbol":"TLX.AU","market":"AU","secType":"STK","nameCN":"TELIX PHARMACEUTICALS LTD","latestPrice":15.58,"timestamp":1787811120000,"preClose":15.49,"halted":0,"volume":1273984,"delay":0,"changeRate":0.00581020012911555,"nameEN":"TELIX PHARMACEUTICALS LTD","floatShares":275410996,"shares":338721355,"eps":0.13264802368545842,"marketStatus":"Closed","change":0.09,"latestTime":"08-27 16:12:00 AEST","open":15.4,"high":15.835,"low":15.17,"amount":19889149,"amplitude":0.042931,"askPrice":15.6,"askSize":5000,"bidPrice":15.45,"bidSize":1650,"shortable":3,"etf":0,"ttmEps":0.13264802368545842,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1787875200000},"marketStatusCode":5,"adr":0,"exchange":"ASX","adjPreClose":15.49,"openAndCloseTimeList":[[1787788800000,1787810400000]],"volumeRatio":0.455743,"lotSize":1,"tradeCurrency":"AUD","auctionPricing":{"symbol":"TLX.AU","preClose":15.49,"auctionPrice":15.57,"auctionVolume":247685,"auctionTime":1787811009356,"referencePrice":15.58,"referenceTime":1787826603092,"auction":3,"marketStatus":"盘后竞价","timestamp":1787811009356}},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"TLX.AU\",,,,,undefined,":{"symbol":"TLX.AU","floatShares":275410996,"roa":"2.71%","roe":"7.36%","lyrEps":-0.029343,"volumeRatio":0.455743,"shares":338721355,"dividePrice":0,"high":15.835,"amplitude":0.042931,"preClose":15.49,"low":15.17,"week52Low":8.26,"pbRate":"7.78","psRate":"4.26","week52High":18.32,"institutionHeld":0,"latestPrice":15.58,"committee":-0.503759,"eps":0.13264802368545842,"divideRate":0,"volume":1273984,"delay":0,"ttmEps":0.13264802368545842,"open":15.4,"prevYearClose":11.2,"prevWeekClose":15.62,"prevMonthClose":14.21,"prevQuarterClose":16.58,"fiveDayClose":17.38,"twentyDayClose":14.07,"sixtyDayClose":12.2},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/TLX.AU\",params:#limit:5,,,undefined,":[{"date":"2026-08-20","symbol":"TLX.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1787184000000,"name":null,"time":"","dateTimestamp":1787148000000,"actualEps":null},{"date":"2026-02-19","symbol":"TLX.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1771455600000,"name":null,"time":"","dateTimestamp":1771419600000,"actualEps":null},{"date":"2026-01-19","symbol":"TLX.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1768777200000,"name":null,"time":"","dateTimestamp":1768741200000,"actualEps":null},{"date":"2025-08-21","symbol":"TLX.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1755734400000,"name":null,"time":"","dateTimestamp":1755698400000,"actualEps":null},{"date":"2025-02-19","symbol":"TLX.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1739919600000,"name":null,"time":"","dateTimestamp":1739883600000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"TLX.AU\",market:\"AU\",,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"TLX.AU\",pageSize:20,pageCount:8,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2628678712","title":"NuWays reiterates Eckert & Ziegler buy rating, sets EUR 23 target price","url":"https://stock-news.laohu8.com/highlight/detail?id=2628678712","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2628678712?lang=en_us&edition=fundamental","pubTime":"2026-04-20 15:01","pubTimestamp":1776668483,"startTime":"0","endTime":"0","summary":"NuWays reiterated a BUY rating on Eckert & Ziegler with a 12-month target price of EUR 23.Report flagged May 12 as date for Q1 2026 results, forecasting sales of EUR 72.5 million.NuWays projected adjusted EBIT of EUR 16 million, implying a 22.1% margin.Medical segment expected to drive growth, with Q1 segment sales seen up 13% to EUR 39 million.Analyst expects no license income in Q1, with remaining Telix-related license revenue of EUR 5.6 million likely later in 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Eckert & Ziegler SE published the original content used to generate this news brief via EQS News, a service of EQS Group AG , on April 20, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260420:nNDL8bg36M:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TLX.AU","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628606227","title":"Telix Pharmaceuticals Says JPMorgan Increases Stake","url":"https://stock-news.laohu8.com/highlight/detail?id=2628606227","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2628606227?lang=en_us&edition=fundamental","pubTime":"2026-04-17 13:35","pubTimestamp":1776404146,"startTime":"0","endTime":"0","summary":"Telix Pharmaceuticals (ASX:TLX) said JPMorgan Chase & Co. and its affiliates have increased their stake in the company on Tuesday to 11.5% or 39 million shares from 7.7% or 26.1 million shares, according to a Friday Australian bourse filing.The company's shares fell past 2% in recent Friday trade.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU0859254822.USD","LU1116320901.HKD","LU0211327993.USD","JPO","LU2756315318.SGD","LU0215105999.USD","TLX.AU","LU0211326839.USD","LU0964807845.USD","LU1917777945.USD","LU2264538146.SGD","BK4585","LU2213496289.HKD","LU1720051017.SGD","LU0345769631.USD","LU2430703251.USD","LU0417517546.SGD","LU0211328371.USD","LU2242649171.HKD","LU1548497426.USD","IE0034235303.USD","LU1084165304.USD","IE00BWXC8680.SGD","LU2746668461.USD","TLX","LU1670628061.USD","LU0345770993.USD","LU0942090050.USD","LU0265550359.USD","BK7067","LU0251132253.USD","BK4139","LU0868494617.USD","JPMO","IE00BDRTCR15.USD","LU2023250843.SGD","LU2237443382.USD","LU2552382132.HKD","BK4550","LU0310799852.SGD","LU2023250504.SGD","LU0106261372.USD","IE00BJTD4N35.SGD","LU1668664300.SGD","IE00BYXW3230.USD","IE00BLSP4239.USD","LU2237443549.SGD","LU2756315664.SGD","LU0203345920.USD","LU1116320737.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627400631","title":"Telix Pharmaceuticals Doses First Patient in Phase 3 Brain Cancer Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2627400631","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627400631?lang=en_us&edition=fundamental","pubTime":"2026-04-15 17:30","pubTimestamp":1776245418,"startTime":"0","endTime":"0","summary":"Telix Pharmaceuticals (TLX) said Wednesday it dosed the initial patient in a Phase 3 clinical trial evaluating its radiopharmaceutical therapy for recurrent glioblastoma, a type of brain cancer.The gl","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["TLX.AU","TLX","BK4139","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1123724179","title":"Stock Track | Telix Pharmaceuticals Plummets 5.11% Intraday Following $600 Million Convertible Bond Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=1123724179","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1123724179?lang=en_us&edition=fundamental","pubTime":"2026-04-15 08:03","pubTimestamp":1776211410,"startTime":"0","endTime":"0","summary":"Telix Pharmaceuticals Ltd (ASX: TLX) saw its shares plummet 5.11% during intraday trading on Wednesday. The sharp decline came amid heightened market activity for the biopharmaceutical company.The...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["TLX.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627420674","title":"Telix Doses First Patient in Phase 3 Ipax-Bright Trial of Tlx101-Tx for Recurrent Glioblastoma","url":"https://stock-news.laohu8.com/highlight/detail?id=2627420674","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627420674?lang=en_us&edition=fundamental","pubTime":"2026-04-15 07:04","pubTimestamp":1776207883,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260414:nTUA7D0BG6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["TLX.AU","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627203064","title":"Telix Doses First Patient in Phase 3 IPAX-BrIGHT Trial of TLX101-Tx for Recurrent Glioblastoma","url":"https://stock-news.laohu8.com/highlight/detail?id=2627203064","media":"prnewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627203064?lang=en_us&edition=fundamental","pubTime":"2026-04-15 06:50","pubTimestamp":1776207000,"startTime":"0","endTime":"0","summary":"The patient was dosed at Austin Health in Melbourne, Australia, under the supervision of Professor Hui Gan. IPAX BrIGHTis assessing the safety and efficacy of TLX101-Tx in combination with chemotherapy , compared to chemotherapy alone. The global, multicenter, open-label study will enroll patients with radiographically confirmed recurrent glioblastoma at first recurrence.IPAX BrIGHT expands upon promising data from earlier trials in the recurrent glioblastoma setting, includingIPAX-1[3], which reported a median overall survival  of 13 months from the initiation of treatment with TLX101-Tx, or 23 months from initial diagnosis[4]. Preliminary results from the IPAX-Linz investigator-initiated trial of TLX101-Tx were consistent and confirmatory to IPAX-1, with a median OS of12.4 monthsfrom initiation of treatment and32.2 monthsfrom initial diagnosis[5]. Beyond the clinical trial setting, an early access program for TLX101-Tx in Europe has dosed 18 patients at first recurrence or later, fur","market":"fut","thumbnail":"https://mma.prnewswire.com/media/1920208/Telix_Main_Logo_Logo.jpg?w=300","type":0,"news_type":0,"thumbnails":["https://mma.prnewswire.com/media/1920208/Telix_Main_Logo_Logo.jpg?w=300"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.prnewswire.com/apac/news-releases/telix-doses-first-patient-in-phase-3-ipax-bright-trial-of-tlx101-tx-for-recurrent-glioblastoma-302742412.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ASX","BK7039","BK4141","BK4543","BK4139","BK7067","SEC.AU","TLX.AU","XAO.AU","XKO.AU","XJO.AU","BK4526","BK7104","GBM.AU","TLX","ASX.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627542704","title":"Telix Successfully Prices and Upsizes US$600 Million Convertible Bonds","url":"https://stock-news.laohu8.com/highlight/detail?id=2627542704","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627542704?lang=en_us&edition=fundamental","pubTime":"2026-04-15 06:41","pubTimestamp":1776206499,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260414:nTUA3RHZKP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","TLX.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627427627","title":"Telix Pharmaceuticals Ltd -  Initial Conversion Price of Convertible Bonds Is US$13.85 per Ordinary Share","url":"https://stock-news.laohu8.com/highlight/detail?id=2627427627","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627427627?lang=en_us&edition=fundamental","pubTime":"2026-04-15 06:14","pubTimestamp":1776204873,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260414:nFWN40X1BN:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","TLX.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627242762","title":"Telix Pharmaceuticals Ltd - Telix Successfully Prices Upsized US$600M Convertible Bonds","url":"https://stock-news.laohu8.com/highlight/detail?id=2627242762","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627242762?lang=en_us&edition=fundamental","pubTime":"2026-04-15 06:14","pubTimestamp":1776204873,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260414:nFWN40X1BN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["TLX.AU","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627441049","title":"Telix Pharmaceuticals Ltd -  Upsizes Convertible Notes Due 2031 to US$600 Milion - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2627441049","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627441049?lang=en_us&edition=fundamental","pubTime":"2026-04-14 21:34","pubTimestamp":1776173680,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260414:nFWN40X0A8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["TLX.AU","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627445663","title":"Top Premarket Decliners","url":"https://stock-news.laohu8.com/highlight/detail?id=2627445663","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627445663?lang=en_us&edition=fundamental","pubTime":"2026-04-14 20:01","pubTimestamp":1776168074,"startTime":"0","endTime":"0","summary":"T1 Energy  shares were 5.7% lower in Tuesday's premarket activity after the company said it is proposing an underwritten public offering of $125 million in convertible senior notes due 2031.CarMax  shares were down 4.2% after the company reported lower fiscal Q4 adjusted earnings and net sales and operating revenue from a year earlier.Telix Pharmaceuticals  stock was 5.1% lower after the company said it commenced a $550 million offering of convertible notes due 2031.Wells Fargo  shares were down 2.4% after the Wall Street bank reported lower-than-expected Q1 revenue.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["IE000M9KFDE8.USD","LU0314106906.USD","LU1267930227.SGD","IE00B19Z3B42.SGD","IE00B7SZLL34.SGD","LU0310799852.SGD","LU2361045086.USD","LU0310800379.SGD","LU0211327993.USD","TLX.AU","LU0154236417.USD","BK4207","BK4588","LU2361044865.SGD","LU1894683348.USD","LU1074936037.SGD","LU0149725797.USD","LU0942090050.USD","LU0048573561.USD","LU1668664300.SGD","LU0130102774.USD","LU0417517546.SGD","LU1035773651.USD","LU0175139822.USD","BK4585","KMX","LU0971096721.USD","LU0640476718.USD","LU0251131958.USD","BK4139","LU0029864427.USD","LU1814569148.SGD","BK4096","LU1267930573.SGD","LU1069347547.HKD","LU0208291251.USD","TLX","LU0106831901.USD","LU0477156953.USD","LU0787776722.HKD","LU2236285917.USD","BK4504","LU0683600562.USD","TE","LU1791807156.HKD","BK4559","IE0002270589.USD","LU1363072403.SGD","LU0251142724.SGD","LU1506573853.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627448835","title":"BRIEF-Telix Pharmaceuticals Launches Offering Of $550 MLN Convertible Notes Due 2031 To Be Issued By Its Unit","url":"https://stock-news.laohu8.com/highlight/detail?id=2627448835","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627448835?lang=en_us&edition=fundamental","pubTime":"2026-04-14 19:06","pubTimestamp":1776164800,"startTime":"0","endTime":"0","summary":"BRIEF-Telix Pharmaceuticals Launches Offering Of $550 MLN Convertible Notes Due 2031 To Be Issued By Its UnitApril 14  - Telix Pharmaceuticals Ltd TLX.AX:TELIX REFINANCES CONVERTIBLE BONDSLAUNCHES AN OFFERING OF US$550 MILLION CONVERTIBLE NOTES DUE 2031 TO BE ISSUED BY ITS WHOLLY-OWNED SUBSIDIARYINITIAL CONVERSION PRICE WILL BE AT A PREMIUM TO TELIX'S CURRENT SHARE PRICE.INTENDED THAT NET PROCEEDS TO BE USED TO REPURCHASE EXISTING CONVERTIBLE BONDS DUE 2029Further company coverage: TLX.AX ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260414:nFWN40W102:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","TLX.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627416477","title":"Telix launches US$550 million convertible notes offering due 2031","url":"https://stock-news.laohu8.com/highlight/detail?id=2627416477","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627416477?lang=en_us&edition=fundamental","pubTime":"2026-04-14 16:36","pubTimestamp":1776155793,"startTime":"0","endTime":"0","summary":"Telix launched offering of US$ 550 million convertible notes due 2031.Net proceeds earmarked for repurchase of existing convertible bonds due 2029.Bookbuild set to determine final terms before market open April 15, 2026.Notes marketed with coupon or yield guidance of 1.5%-1.75%.Conversion premium guided at 35%-37.5% to reference share price set via concurrent delta placement.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260414:nNDLn07nW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TLX.AU","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627416002","title":"Telix Refinances Convertible Bonds","url":"https://stock-news.laohu8.com/highlight/detail?id=2627416002","media":"prnewswire","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627416002?lang=en_us&edition=fundamental","pubTime":"2026-04-14 16:32","pubTimestamp":1776155520,"startTime":"0","endTime":"0","summary":"MELBOURNE, Australia and INDIANAPOLIS, Ind., April 14, 2026 /PRNewswire/ -- Telix Pharmaceuticals Limited   today launches an offering of US$550 million convertible notes due 2031 to be issued by its wholly-owned subsidiary, Telix Pharmaceuticals  Inc. , and guaranteed by Telix and Telix Pharmaceuticals  Inc. . The convertible notes, also referred to as \"convertible bonds\" , are convertible into fully paid ordinary shares in Telix .Managing Director and Group CEO, Dr. Christian Behrenbruch, said: \"The refinance of the existing Convertible Bonds represents our proactive approach to capital management. The new Convertible Bonds will continue to provide the business with cost effective financing.\". The new Convertible Bonds represent attractive, low-cost financing to Telix and are non-dilutive until any potential future conversions occur. The initial conversion price will be at a premium to Telix's current share price.After deduction of commissions, professional fees and other administrat","market":"hk","thumbnail":"https://mma.prnewswire.com/media/1920208/Telix_Main_Logo_Logo.jpg?w=300","type":0,"news_type":0,"thumbnails":["https://mma.prnewswire.com/media/1920208/Telix_Main_Logo_Logo.jpg?w=300"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.prnewswire.com/apac/news-releases/telix-refinances-convertible-bonds-302741509.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4526","TLX.AU","BK4139","SEC.AU","BK4141","BK4543","ASX.AU","BK7067","TLX","ASX","BK7039"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627949068","title":"Telix Pharmaceuticals Ltd - Launches an Offering of US$550 Mln Convertible Notes Due 2031 to Be Issued by Its Wholly-Owned Subsidiary","url":"https://stock-news.laohu8.com/highlight/detail?id=2627949068","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627949068?lang=en_us&edition=fundamental","pubTime":"2026-04-14 14:54","pubTimestamp":1776149677,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260414:nFWN40W102:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","TLX.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627490622","title":"Telix Pharmaceuticals Ltd - Initial Conversion Price Will Be at a Premium to Telix's Current Share Price.","url":"https://stock-news.laohu8.com/highlight/detail?id=2627490622","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627490622?lang=en_us&edition=fundamental","pubTime":"2026-04-14 14:54","pubTimestamp":1776149677,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260414:nFWN40W102:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["TLX.AU","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627897434","title":"Regeneron Pharmaceuticals Inc - Telix Will Receive an Upfront Cash Payment of US$40 Mln From Regeneron","url":"https://stock-news.laohu8.com/highlight/detail?id=2627897434","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627897434?lang=en_us&edition=fundamental","pubTime":"2026-04-13 18:30","pubTimestamp":1776076200,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260413:nTUACB1KYL:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU2362541513.USD","LU2106854487.HKD","REGN","LU2468319806.SGD","LU0058720904.USD","LU0889565916.HKD","LU0823434740.USD","BK4588","LU2237438978.USD","LU0053666078.USD","LU0289739699.SGD","BK7067","LU2023250504.SGD","LU0109394709.USD","LU0823416689.USD","TLX.AU","LU0320765992.SGD","LU0882574055.USD","LU0823434583.USD","LU2089984988.USD","LU2362541273.HKD","BK4139","LU1974910355.USD","LU2362540622.SGD","BK4585","LU0114720955.EUR","LU1917777945.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627483320","title":"BUZZ-Australia's Telix Pharmaceuticals rises on $40 mln Regeneron deal; Citi sees 'broader' scope","url":"https://stock-news.laohu8.com/highlight/detail?id=2627483320","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627483320?lang=en_us&edition=fundamental","pubTime":"2026-04-13 10:38","pubTimestamp":1776047920,"startTime":"0","endTime":"0","summary":"BUZZ-Australia's Telix Pharmaceuticals rises on $40 mln Regeneron deal; Citi sees 'broader' scope** Telix Pharmaceuticals TLX.AX rises as much as 8.8% to A$15.93, highest since November 5, 2025** Stoc","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260413:nL6N40W05T:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2023250504.SGD","LU0289739699.SGD","BK4585","LU0889565916.HKD","LU2362540622.SGD","LU2362541273.HKD","LU0320765992.SGD","LU2106854487.HKD","BK7067","BK4139","BK4588","LU0823434740.USD","LU0058720904.USD","LU0114720955.EUR","LU2362541513.USD","LU1974910355.USD","REGN","LU0053666078.USD","LU0109394709.USD","LU0823416689.USD","TLX.AU","LU2468319806.SGD","LU2237438978.USD","LU0823434583.USD","LU2089984988.USD","LU0882574055.USD","LU1917777945.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1158547007","title":"Stock Track | Telix Pharmaceuticals Soars 7.58% Intraday on Major Regeneron Collaboration Deal","url":"https://stock-news.laohu8.com/highlight/detail?id=1158547007","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1158547007?lang=en_us&edition=fundamental","pubTime":"2026-04-13 08:04","pubTimestamp":1776038653,"startTime":"0","endTime":"0","summary":"TELIX PHARMACEUTICALS LTD (TLX.AU) saw its stock price soar 7.58% during intraday trading on Monday, following a significant corporate announcement.The sharp increase is attributed to the company's...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["TLX.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627101920","title":"Telix and Regeneron Announce Strategic Radiopharma Collaboration","url":"https://stock-news.laohu8.com/highlight/detail?id=2627101920","media":"prnewswire","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627101920?lang=en_us&edition=fundamental","pubTime":"2026-04-13 06:57","pubTimestamp":1776034620,"startTime":"0","endTime":"0","summary":"Telix to receive US$40 million upfront for four initial programs with optionality on a per program basis to co-fund commercialization and profit-share or earnup to an aggregate of US$2.1 billion in developmentand commercial milestone payments pluslow double-digit royalties.","market":"fut","thumbnail":"https://mma.prnewswire.com/media/1920208/Telix_Main_Logo_Logo.jpg?w=300","type":0,"news_type":0,"thumbnails":["https://mma.prnewswire.com/media/1920208/Telix_Main_Logo_Logo.jpg?w=300"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.prnewswire.com/apac/news-releases/telix-and-regeneron-announce-strategic-radiopharma-collaboration-302739967.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2089984988.USD","LU0823434583.USD","LU0058720904.USD","LU0823416689.USD","SEC.AU","TLX.AU","BK4588","BK7039","LU1974910355.USD","LU0109394709.USD","LU0882574055.USD","LU2362541273.HKD","LU0053666078.USD","LU2106854487.HKD","LU2362541513.USD","REGN","BK4585","BK7067","LU0823434740.USD","LU2468319806.SGD","BK4141","LU0289739699.SGD","BK4526","LU2023250504.SGD","BK4139","LU2362540622.SGD","ASX","LU0889565916.HKD","LU2237438978.USD","LU1917777945.USD","TLX","ASX.AU","LU0114720955.EUR","LU0320765992.SGD","BK4543"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":8,"totalSize":198,"code":"91000000","status":"200"}]}}